AstraZeneca shares fall 5% after new cancer drug fails to improve survival
Late-stage lung cancer trial disappointsTreatment was expected to be 'blockbuster'US regulatory approval now in doubtShares in pharmaceutical giant AstraZeneca (AZN), fell more than 5% to a one month low after the UK's largest...
10 September 2024
